Llwytho...
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Two monoclonal antibody (mAb) therapeutics have received emergency use authorization(1,2), and more are in the pi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Res Sq |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Journal Experts
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7852232/ https://ncbi.nlm.nih.gov/pubmed/33532763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21203/rs.3.rs-155394/v1 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|